| Title: |
The comorbidity and co-medication profile of patients with progressive supranuclear palsy |
| Authors: |
Greten, S; Wegner, F; Jensen, I; Krey, L; Rogozinski, S; Fehring, M; Heine, J; Doll-Lee, J; Pötter-Nerger, M; Zeitzschel, M; Hagena, K; Pedrosa, DJ; Eggers, C; Bürk, K; Trenkwalder, C; Claus, I; Warnecke, T; Süß, P; Winkler, J; Gruber, D; Gandor, F; Berg, D; Paschen, S; Classen, J; Pinkhardt, EH; Kassubek, J; Jost, WH; Tönges, L; Kühn, AA; Schwarz, J; Peters, O; Dashti, E; Priller, J; Spruth, EJ; Krause, P; Spottke, A; Schneider, A; Beyle, A; Kimmich, O; Donix, M; Haussmann, R; Brandt, M; Dinter, E; Wiltfang, J; Schott, BH; Zerr, I; Bähr, M; Buerger, K; Janowitz, D; Perneczky, R; Rauchmann, BS; Weidinger, E; Levin, J; Katzdobler, S; Düzel, E; Glanz, W; Teipel, S; Kilimann, I; Prudlo, J; Gasser, T; Brockmann, K; Hoffmann, DC; Klockgether, T; Krause, O; Heck, J; Höglinger, GU; Klietz, M |
| Source: |
Journal of Neurology (2023) (In press). |
| Publisher Information: |
Springer Science and Business Media LLC |
| Publication Year: |
2023 |
| Collection: |
University College London: UCL Discovery |
| Subject Terms: |
Comorbidities; Drug–drug interactions; Polypharmacy; Progressive supranuclear palsy |
| Description: |
Background: Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients. Objectives: To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease. Methods: Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug–drug interactions were evaluated using AiDKlinik®. Results: In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug–drug interactions was higher in PSP patients, especially severe and moderate interactions. Conclusions: PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://discovery.ucl.ac.uk/id/eprint/10179818/ |
| Availability: |
https://discovery.ucl.ac.uk/id/eprint/10179818/1/s00415-023-12006-4.pdf; https://discovery.ucl.ac.uk/id/eprint/10179818/ |
| Rights: |
open |
| Accession Number: |
edsbas.437A1F5F |
| Database: |
BASE |